Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response

The lack of tumor specific antigens (TSA) and the immune tolerance are two major obstacles for the immunotherapy of cancer. Current immune checkpoint inhibitors (ICIs) show clinical responses in only limited subsets of cancer patients, which, to some extent, depends on the mutation load of tumor cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yujia, Li, Siyu, Lv, Jianying, Liu, Yonghui, Chen, Yanan, Liu, Yanhua, Chen, Xiaosu, Li, Jia, Qin, Xuan, Wang, Xiaoshuang, Shi, Jie, Shi, Yi, Xiang, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210591/
https://www.ncbi.nlm.nih.gov/pubmed/34158858
http://dx.doi.org/10.7150/thno.60211

Ejemplares similares

Ejemplares similares